Suppr超能文献

奥美拉唑引起的肾移植患者泌乳-病例报告。

Omeprazole-induced galactorrhea in kidney transplant patients-a case report.

机构信息

Pharmacovigilance Centre, Department of Pharmacy, Jigme Dorji Wangchuk National Referral Hospital, Thimphu, Bhutan.

Graduate Studies, Chulabhorn International College of Medicines, Thammasat University, Bangkok, Thailand.

出版信息

J Med Case Rep. 2022 Mar 27;16(1):121. doi: 10.1186/s13256-022-03337-3.

Abstract

BACKGROUND

Omeprazole belongs to the pharmacological classifications of proton pump inhibitors and is a widely used medicine. All proton pump inhibitors have a common mechanism of action and are prodrugs that require activation in an acidic environment. Omeprazole is extensively metabolized in the liver by cytochrome 2C19 and cytochrome 3A4, which are responsible for drug interactions. Omeprazole-induced galactorrhea is a rare adverse event of drug metabolism and is often underreported.

CASE PRESENTATION

This is a case of a 26-year-old unmarried Asian (Bhutanese) female who underwent kidney transplant and was administered standard antirejection medication (tacrolimus, prednisolone, and leflunomide) along with an antihypertensive agent. She came to the emergency department with complaints of nausea, vomiting, abdominal pain, chronic gastritis, anemia, hypertension, and loss of appetite. The tacrolimus trough level was in the subtherapeutic range at admission. The tacrolimus dose was adjusted, and oral omeprazole was administered. After 3 days, she experienced milk production from her left breast, which according to the patient was her second incidence after omeprazole ingestion.

CONCLUSION

Causality assessment using Naranjo's algorithm and recovering from galactorrhea after stopping omeprazole and omeprazole rechallenge with the reappearance of galactorrhea confirmed omeprazole as the causative agent. Tacrolimus interferes with omeprazole metabolism and increases tacrolimus levels in the blood. Caution needs to be taken when omeprazole is administered with other drugs that interfere with metabolizing enzymes.

摘要

背景

奥美拉唑属于质子泵抑制剂类药物,是一种广泛使用的药物。所有质子泵抑制剂都具有共同的作用机制,且都是前体药物,需要在酸性环境中激活。奥美拉唑在肝脏中主要通过细胞色素 2C19 和细胞色素 3A4 代谢,这两种酶负责药物相互作用。奥美拉唑引起的泌乳是一种罕见的药物代谢不良反应,通常报道较少。

病例介绍

这是一位 26 岁未婚的亚洲(不丹)女性,她接受了肾移植,并接受了标准的抗排斥药物(他克莫司、泼尼松龙和来氟米特)以及一种降压药治疗。她因恶心、呕吐、腹痛、慢性胃炎、贫血、高血压和食欲不振来到急诊部。入院时他克莫司谷浓度处于治疗窗下限。调整了他克莫司剂量,并给予口服奥美拉唑。3 天后,她出现左侧乳房泌乳,据患者自述,这是第二次服用奥美拉唑后出现这种情况。

结论

使用 Naranjo 算法进行因果关系评估,并在停用奥美拉唑和奥美拉唑再挑战后泌乳恢复,证实了奥美拉唑是导致泌乳的原因。他克莫司干扰奥美拉唑代谢,增加血液中他克莫司水平。当与其他干扰代谢酶的药物一起使用奥美拉唑时需要谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e7/8957709/81109f1a212e/13256_2022_3337_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验